logo
Plus   Neg
Share
Email

AstraZeneca: Lynparza Receives Positive CHMP Opinion For Expanded Indication

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending Lynparza (olaparib) as a 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer, AstraZeneca plc (AZN.L,AZN) stated. Lynparza is currently approved in 64 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.

Lynparza, which is being jointly developed by AstraZeneca and MSD or Merck & Co., Inc., is approved for advanced ovarian cancer and metastatic breast cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The New York Times announced its plans to relocate its Hong Kong-based digital news operation to South Korea's Seoul, amid uncertainty following China's tough national security law for the semi-autonomous city. The news organization cited the possible impact of Beijing's new security law to the city's prospects as a hub for journalism in Asia. Search giant Google, Inc. announced Wednesday that it signed an agreement to invest $4.5 billion or 33,737 crore Indian rupees in India's Jio Platforms Ltd, taking a 7.73 percent stake in the company, pending regulatory review in India. This investment by Google values Jio Platforms at an equity value... U.S. Bancorp (USB) reported second quarter earnings per share of $0.41, compared to $1.09, a year ago. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $0.22, for the quarter. Analysts' estimates typically exclude special items. Net income attributable...
Follow RTT